ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Coronavirus

Central Asian nations tighten restrictions as coronavirus spreads

Kazakhstan, Kyrgyzstan, Uzbekistan and Turkmenistan expand countermeasures

Kazakh law enforcement officers wearing protective masks stand guard at a checkpoint, following the state emergency commission's decision to lock down Almaty to prevent the spread of COVID-19, on the outskirts of Almaty, Kazakhstan, on March 19.   © Reuters

ALMATY (Reuters) -- Authorities in Kazakhstan, Kyrgyzstan, Uzbekistan and Turkmenistan have announced fresh restrictions aimed at preventing the spread of coronavirus as the number of cases in Central Asia snowballed.

In Kazakhstan, where 53 cases have been confirmed, authorities said on Saturday they were closing all parks in Almaty, the country's biggest city, which was this week put on lockdown along with capital city Nur-Sultan.

Over the last two days, police and National Guard servicemen have also locked down several residential buildings in Almaty where infected people lived.

In Uzbekistan, with 33 confirmed cases, the government said late on Friday it was shutting down all entertainment venues and tea houses and banning large-scale wedding parties and other family ceremonies.

In Turkmenistan, which has so far reported no coronavirus cases, locals travelling to and from the capital, Ashgabat, said that officials at checkpoints installed around the city informed them that non-essential travel was banned.

The Turkmen government, which earlier suspended all international flights, has made no official announcements on the scope and duration of the new restrictions.

The government of Kyrgyzstan, where the number of coronavirus cases doubled overnight to 12, said on Saturday it was considering declaring a state of emergency from Sunday and has already locked down the provincial districts where the infection had been diagnosed.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media